keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer marker

keyword
https://www.readbyqxmd.com/read/28938635/distribution-of-circulating-tumor-dna-in-lung-cancer-analysis-of-the-primary-lung-and-bone-marrow-along-with-the-pulmonary-venous-and-peripheral-blood
#1
Taichiro Goto, Yosuke Hirotsu, Kenji Amemiya, Takahiro Nakagomi, Daichi Shikata, Yujiro Yokoyama, Kenichiro Okimoto, Toshio Oyama, Hitoshi Mochizuki, Masao Omata
Circulating tumor DNA (ctDNA), extracted from plasma, is a non-invasive surrogate biomarker. However, the distribution of ctDNA in the body still remains to be elucidated. In this study, resected lung tumors, with simultaneous blood and bone marrow samples, were analyzed to elucidate the distribution of ctDNA. Rib bone marrow, pulmonary venous blood (Pul.V) and peripheral blood (Peri.B) were obtained from 30 patients. The liquid samples were divided into cell pellets and supernatant by centrifugation; a total of 212 DNA samples were subjected to massively parallel sequencing...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938549/long-non-coding-rnas-may-serve-as-biomarkers-in-breast-cancer-combined-with-primary-lung-cancer
#2
Xianfeng Ding, Yuhan Zhang, Hongjian Yang, Weimin Mao, Bo Chen, Shifeng Yang, Xiaowen Ding, Dehong Zou, Wenju Mo, Xiangming He, Xiping Zhang
Long non-coding RNAs (lncRNAs) have been shown to play important regulatory role in certain type of cancers biology, including breast and lung cancers. However, the lncRNA expression in breast cancer combined with primary lung cancer remains unknown. In this study, databases of the Cancer Genome Atlas (TCGA) and the lncRNA profiler of contained candidate 192 lncRNAs were utilized. 11 lncRNAs were differentially expressed in breast cancer, 9 candidate lncRNAs were differentially expressed in lung cancer. In order to find the aberrant expression of lncRNAs in breast cancer combined with primary lung cancer, seven samples of primary breast cancer and lung cancer were studied for the expression of selected lncRNAs...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28935465/snhg16-indicates-a-poor-prognosis-and-affects-cell-proliferation-migration-and-invasion-in-non-small-cell-lung-cancer
#3
Wei Han, Xuemei Du, Jing Wang, Lixin Sun, Yongchun Li
In this study, we report that long non-coding RNA (lncRNA) SNHG16 is upregulated in non-small cell lung cancer (NSCLC) tissues, and is correlated with tumor size, TNM stage and lymph node metastasis. Kaplan-Meier analysis shows that the patients with high SNHG16 expression have poorer disease-free survival (DFS) and overall survival (OS) than the patients with low SNHG16 expression. Multivariate Cox regression analysis reveals that SNHG16 expression could be regarded as an independent predictor for DFS and OS in NSCLC patients...
September 18, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28935348/outcomes-after-sleeve-lung-resections-versus-pneumonectomy-in-the-united-states
#4
Zaid M Abdelsattar, K Robert Shen, Sai Yendamuri, Stephen Cassivi, Francis C Nichols, Dennis A Wigle, Mark S Allen, Shanda H Blackmon
BACKGROUND: The current national trends, practice patterns, and outcomes after sleeve resection compared with pneumonectomy in the United States are not known. In addition, whether hospital sleeve-to-pneumonectomy (S:P) ratios are a valid marker of hospital quality is unclear. We describe practice patterns and evaluate the utility of the S:P ratio. METHODS: We identified all patients (N = 23,964) undergoing sleeve resection (n = 1,713) or pneumonectomy (n = 22,251) in the National Cancer Data Base between 1998 and 2012 at 644 hospitals...
September 18, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28935011/-correlation-between-serum-tumor-markers-and-efficacy-of-first-line-egfr-tkis-in-patients-with-advanced-lung-adenocarcinoma
#5
Hanxiao Chen, Xue Yang, Huijun Liu, Kun Ma, Jia Zhong, Zhi Dong, Minglei Zhuo, Yuyan Wang, Jianjie Li, Tongtong An, Meina Wu, Ziping Wang, Jun Zhao
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't receive target therapy following genetic guidance. This study was to explore the relevance between serum tumor markers and treatment of EGFR-TKIs. METHODS: We retrospectively collected the clinical information of advanced lung adenocarcinoma patients harboring EGFR mutation, who received EGFR-TKIs as first-line therapy from June 2009 to June 2014 in Peking University Cancer Hospital, analyzed the relationship between serum tumor markers and efficacy of EGFR-TKIs...
September 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28934754/cntn-1-enhances-chemoresistance-in-human-lung-adenocarcinoma-through-induction-of-epithelial-mesenchymal-transition-by-targeting-the-pi3k-akt-pathway
#6
Ruijie Zhang, Shenghua Sun, Fuyun Ji, Chun Liu, Hua Lin, Lihua Xie, Honghui Yang, Wenxiang Tang, Yan Zhou, Jianping Xu, Pei Li
BACKGROUND/AIMS: Chemoresistance has been a major obstacle to the effective treatment of lung cancer. Previously, we found that contactin-1 (CNTN-1) is related to cisplatin resistance in lung adenocarcinoma. Here, we aimed to investigate the underlying mechanism behind the role of CNTN-1 in cisplatin resistance in lung adenocarcinoma. METHODS: EMT-associated phenotypes, including alterations in cellular morphology and marker (E-cadherin, N-cadherin and Vimentin) expression, were compared between A549 cells and A549/DDP cells (a cisplatin-resistant cell line of lung adenocarcinoma with abnormal CNTN-1 expression) by using real-time time PCR and Western blotting...
September 1, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28932842/microfluidic-isolation-of-platelet-covered-circulating-tumor-cells
#7
Xiaocheng Jiang, Keith H K Wong, Aimal H Khankhel, Mahnaz Zeinali, Eduardo Reategui, Matthew J Phillips, Xi Luo, Nicola Aceto, Fabio Fachin, Anh N Hoang, Wooseok Kim, Annie E Jensen, Lecia V Sequist, Shyamala Maheswaran, Daniel A Haber, Shannon L Stott, Mehmet Toner
The interplay between platelets and tumor cells is known to play important roles in metastasis by enhancing tumor cell survival, tumor-vascular interactions, and escape from immune surveillance. However, platelet-covered circulating tumor cells (CTC) are extremely difficult to isolate due to masking or downregulation of surface epitopes. Here we describe a microfluidic platform that takes advantage of the satellite platelets on the surface of these "stealth" CTCs as a ubiquitous surface marker for isolation...
September 21, 2017: Lab on a Chip
https://www.readbyqxmd.com/read/28932641/response-to-first-line-chemotherapy-regimen-is-associated-with-efficacy-of-nivolumab-in-non-small-cell-lung-cancer
#8
Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange, Emeric Limagne, Romain Boidot, Sylvain Ladoire, Michel Poudenx, Marius Ilie, Paul Hofman, Pierre Saintigny, François Ghiringhelli
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response. We thus examined whether the response to first line chemotherapy could impact on nivolumab benefit. One hundred and 15 patients with NSCLC were included in this retrospective study from 4 different French centers. Forty-three squamous cell carcinomas (SCC), and 72 non-SCC received nivolumab between 2015 and 2016 (3 mg/kg IV Q2W)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28932637/muc1-c-promotes-the-suppressive-immune-microenvironment-in-non-small-cell-lung-cancer
#9
Audrey Bouillez, Dennis Adeegbe, Caining Jin, Xiufeng Hu, Ashujit Tagde, Maroof Alam, Hasan Rajabi, Kwok-Kin Wong, Donald Kufe
The cancer immune microenvironment is of importance for the effectiveness of immunotherapy; however, its dysregulation is poorly understood. The MUC1-C oncoprotein is aberrantly overexpressed in non-small cell lung cancer (NSCLC) and has been linked to the induction of PD-L1. The present work investigated the effects of targeting MUC1-C in an immuno-competent MUC1 transgenic (MUC1.Tg) mouse model. We show that Lewis Lung Carcinoma cells expressing MUC1-C (LLC/MUC1) exhibit upregulation of PD-L1 and suppression of interferon-γ (IFN-γ)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28932634/pd1-positive-tumor-infiltrating-lymphocytes-are-associated-with-poor-clinical-outcome-after-pulmonary-metastasectomy-for-colorectal-cancer
#10
Dagmar Kollmann, Thomas Schweiger, Stefan Schwarz, Desislava Ignatova, Yun-Tsan Chang, Gerrit Lewik, Sebastian F Schoppmann, Wolfram Hoetzenecker, Walter Klepetko, Emmanuella Guenova, Konrad Hoetzenecker
Pulmonary metastasectomy (PM) is routinely performed in colorectal cancer (CRC) patients with oligometastatic spreading to the lungs. Patients with an aggressive tumor phenotype should be excluded from PM, since its benefit is outweighed by early tumor recurrence and impaired prognosis. Expression of PD-1 and its ligands are prognostic factors in a variety of primary tumors. However, their impact on patients' outcome in the setting of PM for CRC has not been evaluated before. 53 CRC patients with pulmonary metastases receiving PM with curative intent were included in this study...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28928901/systematic-correlation-analyses-of-circulating-tumor-cells-with-clinical-variables-and-tumor-markers-in-lung-cancer-patients
#11
Xu Wang, Kewei Ma, Zhiguang Yang, Jiuwei Cui, Hua He, Andrew R Hoffman, Ji-Fan Hu, Wei Li
Measurement of circulating tumor cells (CTC) offers promise as a clinical biomarker to monitor disease status, therapeutic response, and progression in cancer patients. However, its clinical value in lung cancer patients has not been fully explored. We systematically evaluate the association of CTCs with clinical variables and tumor markers in a cohort of lung cancer patients. Using the CELLSEARCH System, CTCs were detected in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients prior to therapy...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28928848/primary-lymphoepithelioma-like-carcinoma-of-the-lung-an-unusual-cancer-and-clinical-outcomes-of-14-patients
#12
Lan Lin, Tingyan Lin, Bangwei Zeng
Advanced lung cancer is considered to exhibit a poor prognosis; however, the pulmonary lymphoepithelioma-like carcinoma (LELC), a rare subtype of non-small cell lung cancer (NSCLC), exhibits an improved prognosis, compared with non-LELC. The present study aimed at investigating the clinical manifestation, imaging characteristics, pathology, tumor markers, treatment and prognosis of primary LELC of the lung. A total of 14 patients with pulmonary LELC were confirmed by surgery and pathology. Clinical data of those patients were retrospectively reviewed including age, sex, smoking history, symptoms, computed tomography (CT) results, Epstein-Barr virus-encoded RNA (EBER) status, treatment and outcomes...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927114/microrna-383-5p-acts-as-a-prognostic-marker-and-inhibitor-of-cell-proliferation-in-lung-adenocarcinoma-by-cancerous-inhibitor-of-protein-phosphatase-2a
#13
Shasha Zhao, Xinyuan Gao, Shuzhi Zang, Yunxia Li, Xianjun Feng, Xiaomei Yuan
Lung cancer is the leading cause of cancer-associated mortality worldwide. MicroRNAs (miRNAs/miRs) serve a role in the occurrence and development of lung cancer. The aim of the present study was to analyze the expression and function of the proliferation-associated miR-383-5p in lung adenocarcinoma (LAC). Samples of human LAC and matched adjacent normal lung tissues were surgically removed, and miR-383-5p expression and the pathological characteristics of lung adenocarcinoma were investigated. The present study revealed that miR-383-5p expression level was significantly decreased in LAC tissues and its expression levels were markedly associated with tumor size and differentiation...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927105/reactive-oxygen-species-driven-mitochondrial-injury-induces-apoptosis-by-teroxirone-in-human-non-small-cell-lung-cancer-cells
#14
Jing-Ping Wang, Chang-Heng Hsieh, Chun-Yen Liu, Kai-Han Lin, Pei-Tsun Wu, Kwun-Min Chen, Kang Fang
Teroxirone as an anticancer agent is used to treat human lung cancer by inducing apoptotic cell death. Previous studies have demonstrated that the status of the tumor suppressor p53 determined the onset of apoptotic cell death in human non-small cell lung cancer cells (NSCLC). In order to further understand the underlying mechanisms of lung cancer, the present study explored the targets of teroxirone. By including antioxidants, the present study analyzed changes in cell proliferation, cell cycle division, mitochondrial membrane potential (MMP), reactive oxygen species (ROS), expression of apoptosis markers and cytochrome c distribution...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927099/interleukin-6-identified-as-an-important-factor-in-hypoxia-and-aldehyde-dehydrogenase-based-gefitinib-adaptive-resistance-in-non-small-cell-lung-cancer-cells
#15
Shi-Min An, Hui-Min Lei, Xu-Ping Ding, Fan Sun, Chun Zhang, Ya-Bin Tang, Hong-Zhuan Chen, Ying Shen, Liang Zhu
Gefitinib resistance and relapse of the disease were the greatest challenges facing clinical therapy of non-small-cell lung cancer (NSCLC). Of note, regarding the hypoxia condition in solid tumor tissues in vivo, roles of hypoxia in gefitinib adaptive resistance and its association with lung cancer stem cells (LCSCs) have not been fully elucidated. In the present study, the role of hypoxia in gefitinib adaptive resistance and its association with aldehyde dehydrogenase (ALDH)-based LCSC gefitinib resistance were comparatively studied using RNA-sequencing (RNA-seq) technology...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927083/expression-of-thymidylate-synthase-predicts-clinical-outcomes-of-s-1-based-chemotherapy-in-squamous-cell-lung-cancer
#16
Yuichiro Honma, Shinsaku Togo, Kazue Shimizu, Miniwan Tulafu, Takuo Hayashi, Toshimasa Uekusa, Shigeru Tominaga, Kenji Kido, Yuichi Fujimoto, Yukiko Nanba, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki, Kazuhisa Takahashi
Non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SCC) histology have limited chemotherapeutic options. Treatment with S-1 combined with carboplatin (CBDCA) has been shown to provide a significant survival benefit in SCC patients compared with treatment with combined CBDCA and paclitaxel. The aim of the present study was to investigate the association between the expression of molecular markers related to the pharmacological action of S-1, including thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT) and dihydropyrimidine dehydrogenase (DPD), and the clinical efficacy of S-1-based chemotherapy in SCC patients...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927035/decreased-expression-of-speckle-type-poz-protein-for-the-prediction-of-poor-prognosis-in-patients-with-non-small-cell-lung-cancer
#17
Jing-Jing Li, Jian-Feng Zhang, Su-Mei Yao, Hua Huang, Shu Zhang, Minxing Zhao, Jian-An Huang
Speckle-type POZ domain protein (SPOP) has been acknowledged as a tumor suppressor gene in numerous types of cancer. However, SPOP expression and its prognostic role in human non-small cell lung cancer (NSCLC) remain unknown. The present study investigated SPOP expression in NSCLC and evaluated its prognostic significance in patients with NSCLC. The results demonstrated that SPOP expression was significantly downregulated in NSCLC tissues at the mRNA and protein level compared with normal lung tissues using reverse transcription-quantitative polymerase chain reaction, and western blot analysis...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28925485/increasing-expression-of-mir-5100-in-non-small-cell-lung-cancer-and-correlation-with-prognosis
#18
T Wang, X Liu, Q Tian, T Liang, P Chang
OBJECTIVE: A previous study indicated that miR-5100 served as a tumor oncogene in lung cancer. However, whether miR-5100 may serve as a novel prognostic marker in non-small cell lung cancer (NSCLC), has not been investigated. The aim of this study was to investigate miR-5100 expression and its clinical significance in NSCLC patients. PATIENTS AND METHODS: Expression of miR-5100 was detected in NSCLC tissues and matched normal lung tissues by quantitative Real-time polymerase chain reaction...
August 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28925087/relationship-of-tumor-pd-l1-cd274-expression-with-lower-mortality-in-lung-high-grade-neuroendocrine-tumor
#19
Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Hironori Ninomiya, Rie Sakakibara, Makoto Nishio, Sakae Okumura, Yuichi Ishikawa
Programmed death-ligand 1 (PD-L1) promotes immunosuppression by binding to PD-1 on T lymphocytes. Although tumor PD-L1 expression is a potential predictive marker of clinical response to anti-PD-1/PD-L1 therapy, little is known about its association with clinicopathological features, including prognosis, in high-grade neuroendocrine tumors (HGNETs), including small-cell lung carcinoma (SCLC) and large-cell neuroendocrine carcinoma (LCNEC), of the lung. We immunohistochemically examined the membranous of expression of PD-L1 in 115 consecutive surgical cases of lung HGNET (74 SCLC cases and 41 LCNEC cases)...
September 18, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28923100/checkpoint-inhibitor-is-active-against-large-cell-neuroendocrine-carcinoma-with-high-tumor-mutation-burden
#20
Victoria E Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal, David Jablons
BACKGROUND: Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinum doublet. However, treatment for patients beyond the first line remains undefined. CASE PRESENTATION: We report the case of a patient with stage IB LCNEC (PD-L1 negative but positive for PD-L1 amplification and tumor mutation burden high) who progressed after adjuvant chemotherapy after surgery and subsequent therapy with an antibody drug conjugate targeting a neuroendocrine-specific cell surface marker but achieved a significant and durable response with pembrolizumab, a humanized IgG4 monoclonal anti-PD-1 antibody...
September 19, 2017: Journal for Immunotherapy of Cancer
keyword
keyword
11501
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"